Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Get Free Report) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 955,300 shares, a decline of 39.2% from the February 13th total of 1,570,000 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average daily volume of 5,260,000 shares, the short-interest ratio is currently 0.2 days.
Virpax Pharmaceuticals Stock Performance
Shares of VRPX opened at $0.17 on Monday. The company’s fifty day moving average is $0.28 and its 200 day moving average is $0.48. Virpax Pharmaceuticals has a fifty-two week low of $0.16 and a fifty-two week high of $4.83.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new stake in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. 32.23% of the stock is owned by hedge funds and other institutional investors.
Virpax Pharmaceuticals Company Profile
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Further Reading
- Five stocks we like better than Virpax Pharmaceuticals
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- How to Build the Ultimate Everything ETF Portfolio
- How to Invest in Blue Chip Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Dividend Capture Strategy: What You Need to Know
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.